World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03066245
Date of registration: 23/02/2017
Prospective Registration: Yes
Primary sponsor: Sophia Al-Adwan
Public title: Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC)
Scientific title: Autologous Bone Tissue Constructed On Biodegradable Polymer for the Treatment of Aneurysmal Bone Cysts
Date of first enrolment: May 3, 2018
Target sample size: 4
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT03066245
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 1/Phase 2
Countries of recruitment
Jordan
Contacts
Name:     Shayma Nazzal, Msc
Address: 
Telephone: 00962795770585
Email: shayma20585@gmail.com
Affiliation: 
Name:     Abdalla Awidi, MD
Address: 
Telephone: 0096265355000
Email: abdalla.awidi@gmail.com
Affiliation: 
Name:     Abdalla Awidi
Address: 
Telephone:
Email:
Affiliation:  University of Jordan
Key inclusion & exclusion criteria

Inclusion Criteria:

- Bone cyst diagnosed with MRI, CT-scan, or X-Ray

- Intact cyst wall with high risk for fracture

- Cysts with minimum diameter of 6mm

- Diagnostic test performed on cyst fluid

- Diagnosed ABC patients whom treatments with other forms of classical therapies ;such
as allograft failed or who are not candidate of autografts

- Provided written consent form

Exclusion Criteria:

- Patients with diagnosis of cancer

- Patients enrolled in other clinical trial



Age minimum: 4 Years
Age maximum: 28 Years
Gender: All
Health Condition(s) or Problem(s) studied
Aneurysmal Bone Cyst
Intervention(s)
Biological: MSC-PLGA
Primary Outcome(s)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the MSC-PLGA engraftment [Time Frame: 3 months]
Secondary Outcome(s)
Effectiveness of using PLGA scaffolds seeded with autologous bone marrow MSCs by Radiograph [Time Frame: 6 months]
Secondary ID(s)
ABCUJCTC
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history